Start here if you're new
what it is
KALA is trying to turn one eye-disease drug candidate into a real company before cash burn turns it into a math problem.
how it gets paid
Last year Kala Bio made $0 in revenue.
what just happened
The clean takeaway is brutal: KALA reported $0 revenue while the latest quarterly EPS landed at -$4.17.
At a glance
C balance sheet — red flag territory — real financial stress
25/100 earnings predictability — expect surprises
-$10.15 fy2024 eps est
$4M fy2022 rev est
1.4 beta
xvary composite: 25/100 — weak
What they do
KALA is trying to turn one eye-disease drug candidate into a real company before cash burn turns it into a math problem.
KALA's edge is focus. It has 43 employees, not a bloated pharma machine, and its lead asset KPI-012 has Orphan Drug and Fast Track status from the FDA. Regulatory designations → special review perks → so what: if data works, you can get to patients faster in a rare eye disease where fewer competitors show up.
How they make money
$0
annual revenue
The products that matter
ai-enabled discovery platform
Researgency.ai
$255M stock story
This is doing most of the narrative work. With only $4M of annual revenue on the page, you are not paying for today's commercial output. You are paying for this to become credible.
core thesis
current operating base
Existing revenue
$4M annual revenue
The existing revenue line is tiny relative to a $255M market cap. That does not kill the story, but it means almost all of the valuation sits on execution that has not shown up in the numbers yet.
not enough yet
capital support
Balance sheet
C grade · $1M debt
The debt load is only $1M, so leverage is not the main problem. The issue is that a company losing money with a C balance sheet and a -66% return on assets has little room for slow progress.
time, not moat
Key numbers
$0M
ttm revenue
This is the whole setup. You are paying for clinical hope because the business is not generating sales yet.
$10.15
fy2024 eps est
Losses this large tell you the company is consuming capital while it waits for proof from trials.
$1M
long-term debt
Debt is low, which helps, but low debt does not fix the bigger problem of having no revenue base.
43
employees
A 43-person company can stay lean, but it also means the execution bench is thin when one program matters most.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $1M (0% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for KALA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The clean takeaway is brutal: KALA reported $0 revenue while the latest quarterly EPS landed at -$4.17.
This is what a pre-revenue biotech looks like. No sales cushion, no margin story, just operating losses narrowing or widening as the pipeline advances.
$0
revenue
$4.17
eps
290%
eps vs. last year
the number that mattered
$0 revenue matters most because it means quarterly EPS is still driven by spending and share count, not customer demand.
source: EDGAR and consensus data, latest reported quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
KALA's biggest risk is specific and simple: Researgency.ai never turns into a real commercial asset. At $255M of market cap on $4M of revenue, there is not much fundamental ballast if that happens.
med
Researgency.ai stays a concept
This is the stock's center of gravity. If the platform fails to show real adoption, partnership value, or credible scientific output, the multiple has nothing hard to lean on.
Impact: with only $4M of annual revenue today, there is no mature operating business underneath to soften the reset.
med
Dilution arrives before proof
Small clinical companies do not get endless time. A C balance sheet, a -$10.15 EPS estimate, and a sub-$1 stock price are not ideal ingredients if fresh capital is needed.
Impact: existing holders can own a smaller piece of the company before the thesis is validated.
med
Thin coverage cuts both ways
There is no target midpoint here and institutional interest looks sparse. In a $255M name, a few buyers can help, but a few exits can also make the chart ugly in a hurry.
Impact: price moves can overshoot both up and down because the shareholder base is smaller and less stable.
If execution slips while financing risk rises, the numbers give you very little cushion: $4M of revenue does not support a $255M valuation on its own.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue above the $4M base
This is the cleanest tell. If commercial traction does not start moving revenue beyond the current $4M level, the platform thesis stays mostly theoretical.
calendar
the next two company updates
You want evidence, not adjectives. Two more updates without harder proof would make the story feel older, not stronger.
risk
any financing before validation
A raise before the core thesis is de-risked usually shifts value from existing holders to new money. In a $0.59 stock, that matters.
trend
whether volatility starts shrinking
The $0–$21 range and 1.4 beta say this still trades like an event stock. If the range tightens, the market may be seeing a clearer path.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: there is no clean consensus because the thesis still needs proof.
risk profile
volatile
1.4 beta and 5 / 100 price stability tell you this is built for swings, not sleep.
chart momentum
catalyst-driven
this name will respond more to proof, financing, and sentiment shifts than to smooth technical trends.
earnings predictability
25/100
predictability this low means the reported numbers are not yet giving investors a stable base case.
source: institutional data
Institutional activity
institutional ownership data for KALA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive